ArticleThe Journal of infectious diseases2015
The Contribution of Ebola Viral Load at Admission and Other Patient Characteristics to Mortality in a Médecins Sans Frontières Ebola Case Management Centre, Kailahun, Sierra Leone, June-October 2014.
Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control.Epidemiology and infection · 2016Pooled it
- Presence and Persistence of Ebola or Marburg Virus in Patients and Survivors: A Rapid Systematic Review.PLoS neglected tropical diseases · 2016Pooled it
- Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease.The Journal of infectious diseases · 2018Trial
- A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.The New England journal of medicine · 2016Trial
- Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.PLoS medicine · 2016Trial
- Trial
- Molecular Phenotypes of Sex- and Age-Specific Differences Relating to Outcome in Patients With Ebola Virus Disease.The Journal of infectious diseases · 2026Article
- Neurological Manifestations in Adult Survivors of Ebola Virus Disease.JAMA neurology · 2026Article
- Recombinant Bombali ebolavirus in cynomolgus macaques as a survival model of Ebola virus disease.Nature communications · 2026Article
- Derivation and Internal Validation of a Mortality Prognostication Machine Learning Model in Ebola Virus Disease Based on Iterative Point-of-Care Biomarkers.Open forum infectious diseases · 2024Article
- Ebola Virus Tropism in Ex Vivo Cynomolgus Macaque Ocular Tissues.The Journal of infectious diseases · 2023Article
- Diagnostics of Ebola virus.Frontiers in public health · 2023Review
- Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.NPJ vaccines · 2022Article
- Article
- Comparison and Evaluation of Real-Time Taqman PCR for Detection and Quantification of Ebolavirus.Viruses · 2021Article
- Factors associated with length of stay and treatment outcome of Ebola patients treated at an Ebola treatment center in Sierra Leone during the peak period of the West African Ebola outbreak 2013-2016.Archives of public health = Archives belges de sante publique · 2021Article
- Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates.PLoS neglected tropical diseases · 2021Article
- Pretest Symptom Duration and Cycle Threshold Values for Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-Transcription Polymerase Chain Reaction Predict Coronavirus Disease 2019 Mortality.Open forum infectious diseases · 2021Article
- Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate.NPJ vaccines · 2020Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper describes patient characteristics, including Ebola viral load, associated with mortality in a Médecins Sans Frontières Ebola case management centre (CMC).Out of 780 admissions between June and October 2014, 525 (67%) were positive for Ebola with a known outcome. The crude mortality rate was 51% (270/525). Ebola viral load (whole-blood sample) data were available on 76% (397/525) of patients. Univariate analysis indicated viral load at admission, age, symptom duration prior to admission, and distance traveled to the CMC were associated with mortality (P < .05). The multivariable model predicted mortality in those with a viral load at admission greater than 10 million copies per milliliter (P < .05, odds ratio >10), aged ≥ 50 years (P = .08, odds ratio = 2) and symptom duration prior to admission less than 5 days (P = .14). The presence of confusion, diarrhea, and conjunctivitis were significantly higher (P < .05) in Ebola patients who died.These findings highlight the importance viral load at admission has on mortality outcomes and could be used to cohort cases with viral loads greater than 10 million copies into dedicated wards with more intensive medical support to further reduce mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.